Sunday, 15 March 2026
PERSPECTA
News from every angle
All
World
Politics
Business
Technology
Finance
Science
Health
Sport
Culture
Opinion
Environment
← Back to headlines
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference
15 Mar, 21:33 — 15 Mar, 21:33
Post
Share
Copy link
Embed
Sources
Sort: Relevance
Sort: Latest
Sort: Bias (L→R)
Sort: Bias (R→L)
Sort: Factuality
left
center
right
Showing 1 of 1 sources
Yahoo
Mostly Factual
1h ago
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference
Read full article →
Something wrong with this story? Report an issue
Related Stories
Teen pregnancies on the rise again
just now
"We must be able to do better"
15m ago
Αυτοκίνητο συγκρούστηκε με μηχανάκι σε διασταύρωση στη Λαμία – Τραυματίστηκε ο δικυκλιστής
17m ago
Dish with 70g of protein – a dietitian prepares it in just 10 minutes
25m ago
Sunday, 15 March 2026
Explore
Log in
Sign up
PERSPECTA
News from every angle
